← Eichor
Condition: Gram Positive Infections Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Gram Positive Infections

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Population Pharmacokinetics of Anti-tuberculosis Drugs in Children With Tuberculosis
Phase N/A · 1 location(s) · Beijing Children's Hospital · NCT03625739A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-A1 in Healthy Young Adults
Phase 1 · 1 location(s) · Vaxcyte, Inc. · NCT07616934Treating Severe Mitral Valve Annular or Valvular Calcification Using Shockwave Balloon SMARTWAVE
NA · 1 location(s) · Prince of Wales Hospital, Shatin, Hong Kong · NCT06952374Dolutegravir Pharmacokinetics Among HIV/TB Coinfected Children Receiving Standard and High-dose Rifampicin
Phase 1 · 1 location(s) · Brigham and Women's Hospital · NCT05069688Clinical Trial of 13-Valent Pneumococcal Conjugate Vaccine
Phase 3 · 1 location(s) · Sinovac Life Sciences Co., Ltd. · NCT06617715Evaluation of IGRA, Symptoms and Chest Radiograph for Subclinical TB Detection in ESRD and KT
Phase N/A · 1 location(s) · Mahidol University · NCT06700876Immunogenicity of COVID-19 Vaccines in Tuberculosis Patients
Phase N/A · 1 location(s) · University of Oxford · NCT05571735Integrating HIV Prevention With TB Household Contact Evaluation in Uganda
NA · 1 location(s) · University of Washington · NCT07119359Adjunctive Clindamycin for the Treatment of Skin and Soft Tissue Infections, a Randomized Controlled Trial
Phase 4 · 1 location(s) · Frieder Schaumburg · NCT05899140Hotspots, Households and Hospitals: Enhanced Drug-resistant Tuberculosis Case Finding in Namibia
Phase N/A · 1 location(s) · University of Namibia · NCT05022238FMT in Initial CDI
NA · 1 location(s) · Turku University Hospital · NCT05257538Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective
Phase N/A · 1 location(s) · Institut Pasteur du Cambodge · NCT07358910Serum Collection Study for Assay Development
Phase 1 · 1 location(s) · GPN Vaccines · NCT07205289ID93+GLA-SE Vaccine Against Tuberculosis in Older Adults Aged 55-74
Phase 1 · 4 location(s) · Quratis Inc. · NCT06714513mulTiplex Immunoassay qualiTy assuRance Panel
Phase N/A · 1 location(s) · St George's, University of London · NCT07562061Clinical Trial to Evaluate the Efficacy and Safety of EEC for the Diagnosis of Mycobacterium Tuberculosis Infection in P
Phase 3 · 8 location(s) · Chengdu CoenBiotech Co., Ltd · NCT07152639Program for Rifampicin-Resistant Disease With Stratified Medicine for Tuberculosis
Phase 2/Phase 3 · 6 location(s) · University of California, San Francisco · NCT06441006Rescue Fecal Microbiota Transplantation for National Refractory Intestinal Infections
Phase N/A · 1 location(s) · The Second Hospital of Nanjing Medical University · NCT03895593Safety of Administering Isoniazid to SLE Patients to Prevent TB
Phase 2/Phase 3 · 1 location(s) · Universitas Padjadjaran · NCT06618573Telacebec (T) Treatment in Adults With Buruli Ulcer (BU). (TREAT BU)
Phase 2 · 2 location(s) · Barwon Health · NCT06481163Tuberculosis in Rural and Malnourished Populations
NA · 1 location(s) · University of Virginia · NCT06971952FMT Capsules for rCDI
Phase 3 · 1 location(s) · Helsinki University Central Hospital · NCT07458984Rapid Research in Diagnostics Development for TB Network
NA · 16 location(s) · University of California, San Francisco · NCT04923958TGF β 1 Expression Related Gene Polymorphism
Phase N/A · 1 location(s) · Aswan University · NCT0668369018F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) in Tuberculosis Patients
Phase N/A · 1 location(s) · Children's Hospital Medical Center, Cincinnati · NCT07077213Outcomes and Data Collection for Fecal Microbiota Transplantation for the Treatment of Recurrent Clostridium Difficile
NA · 1 location(s) · Krunal Patel · NCT03562741Bedaquiline Enhanced Post ExpOsure Prophylaxis for Leprosy
Phase 3 · 1 location(s) · Institute of Tropical Medicine, Belgium · NCT05597280Adjunctive Doxycycline for Central Nervous System Tuberculosis
Phase 2 · 6 location(s) · National University Hospital, Singapore · NCT06446245The Safety, Completion Rate and Prevention Effect by Rifamycin-containing Regimens for Latent Tuberculosis Infection in
Phase 4 · 1 location(s) · National Taiwan University Hospital · NCT05588492Environmental Reservoirs of Non-tuberculous Mycobacteria in Cystic Fibrosis Households: A Case-control Study of Exposure
Phase N/A · 2 location(s) · Research Center Borstel · NCT07369414
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.